Sunil R. Hingorani, MD, PhD
PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.
The drug, which is a PEGylated recombinant human hyaluronidase enzyme, is being tested in combination with standard-of-care gemcitabine and nab-paclitaxel (Abraxane) in patients with stage IV treatment-naïve pancreatic cancer whose tumors express high levels of hyaluronan (HA). PEGPH20 degrades HA, a carbohydrate that can build up in the tumor microenvironment and block the delivery of anticancer therapies.
The phase III, randomized, multicenter HALO- 301 trial seeks to recruit approximately 420 patients with advanced, metastatic pancreatic ductal adenocarcinoma, including patients with disease progression that occurs following resection 6 months or longer after their last therapy (NCT02715804). (Figure).
... to read the full story